tissue factor pathway inhibitor (EntreMed/Affymax)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug Nametissue factor pathway inhibitor (EntreMed/Affymax)
Drug Alias NameTFPIc23TFPI (EntreMed/Affymax)tissue factor pathway inhibitor (EntreMed)TFPI (EntreMed)
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionFibroblast growth factor 2 inhibitors
TargetsFibroblast growth factor 2
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesCasi Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAffymax IncCasi Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A